Alpha 2.0
Login Register
» Authors » Lode Schuerman

Lode Schuerman

Explore the profile of Lode Schuerman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 94
Citations 1821
Followers 0
Related Specialties
Allergy & Immunology
Pediatrics
General Medicine
Top 10 Co-Authors
Dorota Borys
Marta Moreira
Patricia Lommel
Nancy Francois
Roman Prymula
Ilse Dieussaert
Marc Lievens
Jan Poolman
Jeanne-Marie Jacquet
Daniel Ansong
Published In
Pediatr Infect Dis J
Vaccine
Hum Vaccin Immunother
Lancet Infect Dis
Expert Rev Vaccines
Affiliations
Soon will be listed here.
Recent Articles
1.
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
Westercamp N, Osei-Tutu L, Schuerman L, Kariuki S, Bollaerts A, Lee C, et al.
J Infect Dis . 2024 Mar; 230(2):e486-e495. PMID: 38438123
Background: The RTS,S/AS01E (RTS,S) malaria vaccine is recommended for children in malaria endemic areas. This phase 2b trial evaluates RTS,S fractional- and full-dose regimens in Ghana and Kenya. Methods: In...
2.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M, et al.
EClinicalMedicine . 2023 Nov; 64:102168. PMID: 37936652
Background: The literature on first generation COVID-19 vaccines show they were less effective against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and BA.5 subvariants). New vaccines developed...
3.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M, et al.
Lancet Respir Med . 2023 Sep; 11(11):975-990. PMID: 37716365
Background: COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed to describe the clinical efficacy and safety...
4.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
de Bruyn G, Wang J, Purvis A, Ruiz M, Adhikarla H, Alvi S, et al.
EClinicalMedicine . 2023 Aug; 62:102109. PMID: 37533419
Background: In a parallel-group, international, phase 3 study (ClinicalTrials.govNCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein booster vaccines with AS03-adjuvant (CoV2 preS dTM-AS03). Methods: Adults, previously...
5.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M, et al.
medRxiv . 2022 Dec; PMID: 36523415
Background: COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. Methods: We conducted a global Phase 3, multi-stage efficacy study...
6.
Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
Marijam A, Schuerman L, Izurieta P, Pereira P, Van Oorschot D, Mehta S, et al.
Hum Vaccin Immunother . 2022 Dec; 18(7):2135916. PMID: 36507685
Vaccine impact models against rotavirus disease (RD) and pneumococcal disease (PD) in low- and middle-income countries assume vaccine coverage based on other vaccines. We propose to assess the impact on...
7.
Efficacy of RTS,S/AS01 malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
Samuels A, Ansong D, Kariuki S, Adjei S, Bollaerts A, Ockenhouse C, et al.
Lancet Infect Dis . 2022 Jun; 22(9):1329-1342. PMID: 35753316
Background: Controlled infection studies in malaria-naive adults suggest increased vaccine efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first results of an ongoing trial assessing different fractional-dose regimens...
8.
Assessing the safety, impact and effectiveness of RTS,S/AS01 malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up
Praet N, Asante K, Bozonnat M, Akite E, Ansah P, Baril L, et al.
Malar J . 2022 Apr; 21(1):132. PMID: 35468801
Background: Following a 30-year development process, RTS,S/AS01 (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating...
9.
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sridhar S, Joaquin A, Bonaparte M, Bueso A, Chabanon A, Chen A, et al.
Lancet Infect Dis . 2022 Jan; 22(5):636-648. PMID: 35090638
Background: We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2 preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-injection dosing schedule in a previous phase 1-2...
10.
Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial
Rinta-Kokko H, Palmu A, Ruokokoski E, Nieminen H, Moreira M, Schuerman L, et al.
PLoS One . 2022 Jan; 17(1):e0261750. PMID: 34986178
Background: In the nation-wide double-blind cluster-randomised Finnish Invasive Pneumococcal disease trial (FinIP, ClinicalTrials.gov NCT00861380, NCT00839254), we assessed the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine...